

Prostate cancer diagnosis

Poster Session 62

Monday, 14 March
08:45 - 10:15

Location: Room 14c (ICM, Level 1)

Chairs: N. Al-Hamdani, Baghdad (IQ)
F.M.J. Debruyne, Arnhem (NL)
V. Scattoni, Milan (IT)

Aims and objectives of this presentation

This session is aiming to find the best and specific way for early diagnosis and detection of prostate cancer and the best way to prevent the disease if possible.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *776 **Prostate cancer incidence and cardiovascular mortality among users of testosterone replacement therapy in the Finnish Prostate Cancer Screening Trial**
By: [Murtola T.](#)¹, [Rytkönen J.](#)², [Talala K.](#)³, [Taari K.](#)⁴, [Tammela T.](#)², [Auvinen A.](#)⁵
Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Finnish Cancer Registry, Dept. of Statistics, Helsinki, Finland, ⁴University of Helsinki, Medical School, Helsinki, Finland, ⁵University of Tampere, School of Health Sciences, Tampere, Finland
- *777 **The impact of age-adjusted Charlson comorbidity index and age-adjusted prostate cancer specific comorbidity index in men underwent radical prostatectomy: A competing risk analysis of long-term survival data**
By: [Kang D.H.](#)¹, [Lee J.Y.](#)¹, [Jang W.S.](#)¹, [Kang H.W.](#)², [Kwon J.K.](#)¹, [Rha K.H.](#)¹, [Cho N.H.](#)³, [Oh C.K.](#)⁴, [Choi Y.D.](#)¹, [Hong S.J.](#)¹, [Cho K.S.](#)¹
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, ²Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, ³Yonsei University College of Medicine, Dept. of Pathology, Seoul, South Korea, ⁴Inje University College of Medicine, Dept. of Urology, Busan, South Korea
- *778 **Increase prostate cancer detection rate from 12- to 18-core prostate biopsy in patients with serum prostate-specific antigen level of 4.0-20.0 ng/ml**
By: [Wang B-R.](#)¹, [Chen C.C.](#)², [Ou Y-C.](#)²
Institutes:¹Taichung Arm Force General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan, ²Taichung Veterans General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan
- *779 **Comparison of MRI/ultrasound-fusion-biopsy to systematic prostate biopsy in prediction of final histopathology in prostatectomy specimen**
By: [Borkowetz A.](#)¹, [Platzek I.](#)², [Toma M.](#)³, [Renner T.](#)¹, [Fröhner M.](#)¹, [Zastrow S.](#)¹, [Wirth M.](#)¹
Institutes:¹University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, ²University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, ³University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany
- *780 **Minimizing the Gleason score upgrade from biopsy to prostatectomy specimen through mpMRI and template mapping fusion biopsy**
By: [Gross O.](#), [Neuhaus L.](#), [Mortezavi A.](#), [Sulser T.](#), [Eberli D.](#)
Institutes:University Hospital Zurich, Dept. of Urology, Zürich, Switzerland

- *781 **Natural history of prostatic precancerous lesions: When to re-biopsy?**
By: Oderda M.¹, Agnello M.¹, Barale M.¹, Falcone M.¹, Marra G.¹, Preto M.¹, Daniele L.², Pacchioni D.², Delsedime L.², Nicolaiew N.³, Joniau S.³, De La Taille A.⁴, Gontero P.¹
Institutes:¹University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, ²A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, ³University Hospitals of Leuven, Dept. of Urology, Leuven, Belgium, ⁴C.H.U. Henri Mondor, Dept. of Urology, Creteil, France
- *782 **Assessing the role of time from prostate cancer diagnosis to radical prostatectomy: Can surgery be postponed safely?**
By: Cucchiara V., Suardi N., Gallina A., Stabile A., Picozzi M., Zaffuto E., Fossati N., Gandaglia G., Larcher A., Salonia A., Montorsi F., Briganti A.
Institutes:IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy
- *783 **High-resolution magnetic resonance imaging differentiates between normal histomorphological signatures and prostate cancer in the resected prostate gland**
By: Durand M.¹, Jain M.², Robinson B.³, Aronowitz E.⁴, El Douahy Y.², Leung R.², Sherr D.², Ng A.⁴, Donzeau D.⁵, Amiel J.⁵, Pascal S.⁴, Villers A.⁶, Ballon D.⁴
Institutes:¹Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, INSERM U1189, Dept. of Urology, Nice, France, ²Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America, ³Weill Medical College of Cornell University, Dept. of Pathology, New York, United States of America, ⁴Weill Medical College of Cornell University, Dept. of Radiology, New York, United States of America, ⁵Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, Dept. of Urology, Nice, France, ⁶CHU Lille, Université De Lille, INSERM U1189, Dept. of Urology, Lille, France
- *784 **Impact of PI-RADS version 2 on MRI diagnosis for extracapsular extension of prostate cancer: A multireader study**
By: Matsuoka Y.¹, Ishioka J.¹, Tanaka H.², Inoue M.¹, Ito M.¹, Yoshida S.¹, Yokoyama M.¹, Numao N.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan
- *785 **Limitations in elastography based prostate biopsy**
By: Grindei-Nevrincean M.¹, Schiffmann J.¹, Tian Z.², Yassin D-J.¹, Steinwender T.¹, Leyh-Bannurah S-R.², Randazzo M.³, Kwiatkowski M.³, Karakiewicz P.I.², Hammerer P.¹, Manka L.¹
Institutes:¹Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany, ²University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada, ³Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland
- *786 **Phenotypic and molecular characterization of circulating tumor cells (EGFR and AR) and its correlation with prostate biopsy in early-stage prostate cancer**
By: Puche Sanz L.¹, Flores-Martín J.¹, Vázquez Alonso F.¹, Serrano Fernández M.J.², Cózar Olmo J.M.¹
Institutes:¹Complejo Hospitalario Universitario De Granada, Dept. of Urology, Granada, Spain, ²Centro Pfizer-Universidad De Granada-Junta De Andalucía De Genómica E Investigación Oncológica (GENY), Dept. of Circulating Tumor Cells, Granada, Spain